Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
News|Articles|August 29, 2022
Revisions to Annex 1 Officially Published
Author(s)Pharmaceutical Technology Editors
The European Union publishes long-awaited changes to Annex 1.
Advertisement
The European Union officially released its revisions to its good manufacturing practice Annex 1 regulatory document on Aug. 25, 2022. These regulations, which pertain to manufacturing sterile drugs in the EU, are set to go into effect exactly one year after its publication, on Aug. 25, 2023.
According to the revised Annex 1: “The GMP/GDP Inspectors Working Group and the PIC/S Committee jointly recommend that the current version of annex 1, on the manufacture of sterile medicinal products, is revised to reflect changes in regulatory and manufacturing environments. The new guideline should clarify how manufacturers can take advantage of new possibilities deriving from the application of an enhanced process understanding by using innovative tools as described in the ICH Q9 and Q10 guidelines” (1).
Originally published in 2008, Annex 1 was most recently revised in 2020. Following the most recent revisions, Annex 1 sits at 59 pages; and when it was originally published it had 16.
Reference
- EU, Annex 1, vol. 4, page 1, Annex 1: Manufacture of Sterile Medicinal Products (August 2022).
Source:
Advertisement
Related to this article
The FDA has approved remibrutinib for symptomatic dermographism, the first such therapy, extending an oral BTK inhibitor label via the Phase III RemIND trial.
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Winners of the 2026 CPHI Pharma Awards Announced
2
Thermo Fisher Scientific Exhibits New Solutions and Expanded Capabilities at CPHI Milan
3
CPHI Milan 2026: Nitrosamine Risk Mitigation, Part 1
4
Can Continuous Tableting End Scale-Up for Complex Oral Drugs?
5